Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-3 nivolumab plus TACE/TAE in intermediate-stage hepatocellular carcinoma
2024-513882-38-00Phase 3Authorised
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Oct 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab, mitomycin c, doxorubicin, cisplatin, epirubicin and 2 more in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoints: Time to TACE/TAE progression and Overall survival. Planned start Oct 2022; status: authorised.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-513882-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513882-38-00.